| US 7,570,992 B2 | ||
| Electrical field therapy with reduced histopathological change in muscle | ||
| Edward Nolan, San Diego, Calif. (US); Dietmar P. Rabussay, Solana Beach, Calif. (US); Georg Widera, Del Mar, Calif. (US); and Lei Zhang, San Diego, Calif. (US) | ||
| Assigned to Genetronics, Inc., San Diego, Calif. (US) | ||
| Filed on Jan. 13, 2004, as Appl. No. 10/756,946. | ||
| Application 10/756946 is a continuation of application No. 10/165657, filed on Jun. 07, 2002, granted, now 6,678,556. | ||
| Application 10/165657 is a continuation in part of application No. 09/625825, filed on Jul. 26, 2000, granted, now 6,654,636. | ||
| Application 09/625825 is a continuation in part of application No. 09/352809, filed on Jul. 13, 1999, granted, now 6,697,669. | ||
| Claims priority of provisional application 60/126058, filed on Mar. 25, 1999. | ||
| Claims priority of provisional application 60/109324, filed on Nov. 20, 1998. | ||
| Claims priority of provisional application 60/092544, filed on Jul. 13, 1998. | ||
| Prior Publication US 2004/0147964 A1, Jul. 29, 2004 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61N 1/30 (2006.01); A61M 31/00 (2006.01) | ||
| U.S. Cl. 604—21 [604/501] | 36 Claims |
| 1. A method for delivering a therapeutic agent to a subject, comprising;
introducing an effective amount of at least one therapeutic agent into a target muscle tissue site of a subject, wherein the
therapeutic agent comprises a polynucleotide that encodes a therapeutic protein or peptide; and
generating an electric field at the target muscle tissue site by introducing from 1 to about 4 monopolar DC pulses, each pulse
having a duration of about 10 ms to about 100 ms, to generate a nominal field strength of about 100 V/cm to about 300 V/cm
at the target muscle tissue site.
|